ATRN-119 — Investigational Agent
Other · Phase 1 · Aprea Therapeutics
Mechanism of Action
ATRN-119 is an oral macrocyclic ATR kinase inhibitor that disrupts the replication-stress response, driving synthetic lethality in tumors with DNA damage-response defects such as ATM loss.
Investigational Indications
- DNA damage-response deficient ovarian cancer
- Advanced solid tumors with replication stress